⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 18 in last 7 days 🍎 Food: 180 in last 7 days 🧸 Products: 48 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 3 hours ago
🛡️ EUSW
🇬🇧
💊 Medicine AT March 2, 2026

ZYPADHERA 405 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension 405 mg (Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension)

📷 Wikipedia: Olanzapine · Source
ZYPADHERA 405 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension 405 mg (Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension)
📷 Wikipedia: Olanzapine · Source
ZYPADHERA 405 mg powder and solvent for preparing a depot injection suspension 405 mg is temporarily unavailable due to a delay in finished product release. No further details are provided.
Resolved by agency
The issuing agency has confirmed this medicine alert is over — the underlying issue was addressed. Originally reported 86 days ago.
📈 Timeline
2 days in total
May 18, 2026 May 20, 2026

What is this? Zypadhera is a long-acting injection used to treat serious mental health problems. It contains the medicine olanzapine.

What's happening? The injection is not available right now because of a delay in making it. It should come back in May.

Does this affect me? If you use this medicine, you may not be able to get it until it’s back in stock.

What should I do? Talk to your pharmacist or doctor about other treatment options until it’s available again.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
Agency-published detail

🚫 Parallel export ban active · ATC: N05AH03 · Reason: Verzögerung in der Freigabe des Fertigproduktes · Marketing authorisation holder: Cheplapharm Registration GmbH, Weiler Straße 5e, 79540 Lörrach, Federal Republic of Germany · Affected packs: 1 Stück Schachtel, Durchstechflasche, Durchstechflasche [Nicht verfügbar, since 2026-03-10, resupply 2026-05-25]

First published
March 2, 2026
Last refreshed by us
1 week ago
Severity (as classified)
Medium
Official source
https://medikamente.basg.gv.at/en/medicine-shortage

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

Related alerts

❓ Frequently asked questions

What is this medicine shortage alert about?
ZYPADHERA 405 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension 405 mg (Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension). ZYPADHERA 405 mg powder and solvent for preparing a depot injection suspension 405 mg is temporarily unavailable due to a delay in finished product release. No further details are provided.
When was this alert issued?
This alert was issued on March 2, 2026 by BASG (Austria).
Which countries are affected?
The alert applies to Austria.
How serious is this alert?
Medium risk. A medium risk means harm is possible under certain conditions. Read the notice and act on the recommended steps.
What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
Where can I find the official notice?
The full official notice is published on medikamente.basg.gv.at.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.